Pain medication is the number one sold prescription drug sold (in quantity) and has a major financial effect all sectors of society. More people are affected by pain in the United States than cardiovascular disease, stroke, diabetes, and cancer combined.
PubMed Research and Erchonia specific research has proven significant effectiveness using Low Level Laser Therapy, as a standalone, for reduction of pain, improved tissue regeneration, decrease inflammation, increase circulation, ATP synthesis etc.
PubMed Research is clear that a dose of 1 - 5 joules/cmprovides optimum regeneration benefits. The FDA clearances Erchonia has achieved are neck, shoulder, foot and low back pain and the doses were using 3 - 10 minutes of Erchonia laser. Choose the amount of time that works best in your office procedures
There are many beneficial pain frequency settings used during therapeutic dose as well as Upregulation that I will share. The Erchonia Laser will provide metabolic efficiency to any professional licensure and technique application.
With 3-dimensional exam it is common to identify systemic treatment corrections (for subacute and chronic), such as the cervical spine related to tennis elbow or carpal tunnel, brain and low back pain, low back related to plantar fasciitis, etc. or a variety of SYSTEM combinations true for the individual.
Current FDA Cleared Pain conditions (more to come).
Jan 17, 2002-1st FDA market clearance: 635 nm laser; Chronic neck and shoulder pain k012580
April 2014 Erchonia FX635 Reducing chronic heel pain arising from plantar fasciitis K132940
FDA market cleared to treat chronic, acute, and post-operative pain K041139, K072206.
May 21, 2018 Chronic Low Back Pain K180197
June 2019 Nociceptive Musculoskeletal Pain K190572
August 8, 2019 FDA market cleared EVRL to treat Chronic neck and shoulder pain K191257
September 1st, 2022 Erchonia GVL for adjunctive use chronic neck and shoulder pain of musculoskeletal origin K221987
Previous Erchonia clearances from the FDA have already set Erchonia doctors apart from the rest of the therapeutic industry. All previous Pain related FDA Clearances have been limited to specific areas of the body. Now Erchonia has the only whole-body indication based on Level 1 clinical data. Based on these results, the fact that there are no known negative side effects, and that it's non-addictive, Erchonia low-level laser technology should be considered first. It's more effective than opioids or NSAIDS when treating chronic musculoskeletal pain when you compare the SPACE study results with those Erchonia submitted to the FDA.
